DENOSUMAB VERSUS ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH METASTATIC BONE DISEASE: SUBGROUP ANALYSES BY BASELINE CHARACTERISTICS

被引：0
|
作者：
Stopeck, A. [1 ]
Lipton, A. [2 ]
Fizazi, K. [3 ]
Smith, M. R. [4 ,5 ]
Shore, N. D. [6 ]
Martin, M. [7 ]
Vadhan-Raj, S. [8 ]
Zhou, K. [9 ]
Balakumaran, A. [9 ]
Braun, A. H. [9 ]
机构：
[1] Univ Arizona, Ctr Canc, Tucson, AZ USA
[2] Penn State Hershey Med Ctr, Hershey, PA USA
[3] Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[4] Massachusetts Gen Hosp, Ctr Canc, Dept Hematol, Boston, MA USA
[5] Massachusetts Gen Hosp, Ctr Canc, Dept Oncol, Boston, MA USA
[6] Atlantic Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC USA
[7] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[8] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Sect Cytokines & Support Oncol, Houston, TX 77030 USA
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [31] An Italian survey on the use of denosumab for the management of skeletal-related events in patients with bone metastases
    Berardi, R.
    Berruti, A.
    Brogelli, L.
    Zucali, P. A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (13) : 4659 - 4665
  • [32] Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastasis from Solid Tumor
    Iranikhah, Maryam
    Wilborn, Teresa W.
    Wensel, Terri M.
    Ferrell, Jodi B.
    PHARMACOTHERAPY, 2012, 32 (03): : 274 - 284
  • [33] Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
    Dranitsaris, George
    Hatzimichael, Eleftheria
    SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1353 - 1360
  • [34] Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreasbiliary system cancer, and other rare cancers
    Imai, Hiroo
    Saijo, Ken
    Yamada, Hideharu
    Ohuchi, Kota
    Okada, Yoshinari
    Komine, Keigo
    Takahashi, Masahiro
    Takahashi, Shin
    Takahashi, Masanobu
    Shimodaira, Hideki
    Ishioka, Chikashi
    JOURNAL OF BONE ONCOLOGY, 2017, 6 : 37 - 40
  • [35] Denosumab In the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumours
    Scott, Lesley J.
    Muir, Victoria J.
    DRUGS, 2011, 71 (08) : 1059 - 1069
  • [36] Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Coleman, RE
    Schulman, KA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (01): : 8 - 16
  • [37] COMPARING THE EFFICACY OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SRES): A CRITICAL APRAISAL OF THREE PIVOTAL TRIALS
    Strite, S.
    Stuart, M. E.
    Beckman, V
    Oehrling, K.
    VALUE IN HEALTH, 2015, 18 (03) : A192 - A193
  • [38] Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis
    Yerram, Prakirthi
    Kansagra, Shraddha
    Abdelghany, Osama
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (03) : 179 - 184
  • [39] Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
    George Dranitsaris
    Eleftheria Hatzimichael
    Supportive Care in Cancer, 2012, 20 : 1353 - 1360
  • [40] Osteoprotection with Denosumab in oncological Female Patients Reducing Skeletal-related Events in osseous metastatic Tumors
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (09)
12345